Stereochemistry | ABSOLUTE |
Molecular Formula | C21H25Cl2FO5 |
Molecular Weight | 447.325 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12C[C@H](Cl)[C@@]3(Cl)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
InChI
InChIKey=VTWKPILBIUBMDS-OTJLYDAYSA-N
InChI=1S/C21H25Cl2FO5/c1-18-4-3-10(26)5-13(18)14(24)6-12-11-7-16(27)21(29,17(28)9-25)19(11,2)8-15(22)20(12,18)23/h3-5,11-12,14-16,25,27,29H,6-9H2,1-2H3/t11-,12-,14-,15-,16+,18-,19-,20-,21-/m0/s1
Molecular Formula | C21H25Cl2FO5 |
Molecular Weight | 447.325 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Fluclorolone is a synthetic glucocorticoid corticosteroid which was never marketed. The acetonide cyclic ketal of fluclorolone, fluclorolone acetonide is a corticosteroid for topical use on the skin. Fluclorolone is a glucocorticoid receptor agonist. It was used for the treatment of atopic dermatitis, varicose eczema and psoriasis.
Approval Year
PubMed
Sample Use Guides
A double-blind trial comparing fluclorolone acetonide 0.025 % in FAPG base with the base alone was carried out on 18 female patients with varicose eczema. In 2 patients both legs were affected and treated. All the patients were routinely treated by compression sclerotherapy and the areas of eczema dressed once weekly with one or other of the creams until the eczema had cleared or there had been 4 visits with little or no improvement. Eight out of 10 patients treated with the active cream healed after one application and 1 patient after a second application, compared with only 1 patient healed and 1 showing some improvement on the base alone.
Route of Administration:
Topical